TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14585211
Drug: bivalent HIV
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent HIV gp120 SF2/CM235 vaccine
Study: 10938184
Drug: Hydroquinidine (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroquinidine (450 mg/day)
Study: 8751695
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at 4 ml/sec with a 25-sec scan delay
Study: 8751695
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at 4 ml/sec with a 20-sec scan delay
Study: 8751695
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at 2 ml/sec with a 30-sec scan delay
Study: 8751695
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at 2 ml/sec
Study: 8751695
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at 4 ml/sec
Study: 1574965
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (r-HuEPO) at a dose of 100 U/kg given intravenously twice weekly for 6 weeks
Study: 31269914
Drug: High Intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Intensity Interval Training (HIIT) for 8 weeks, 3 times weekly, with an average of 78 ± 5.1 minutes of exercise completed out of 90 minutes.
Study: 29703226
Drug: Individualised Modular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised Modular Treatment Programme (IMTP) - 10 sessions of individual cognitive behavioural therapy with adolescents and/or parents, focusing on three out of ten available modules.
Study: 20499357
Drug: Once-yearly i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-yearly i.v. infusion of ZOL 5 mg
Study: 20499357
Drug: Once-weekly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly oral ALN 70 mg
Study: 9850068
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg twice a day) plus rhEPO (12,000-30,000 units per week)
Study: 2670659
Drug: Sucralfate suspension,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate suspension, 4 g/day (10 ml four times a day)
Study: 2449021
Drug: Cimetidine 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1.6 g daily
Study: 6786895
Drug: Cimetidine 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 0.8 g daily
Study: 27859629
Drug: Intravenous Escherichia
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Escherichia coli lipopolysaccharide (LPS)
Study: 26118427
Drug: Alisporivir (ALV)
Normalized name: ALV-001
DrugBank: Alisporivir (DB12139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisporivir (ALV) 1,000 mg once-daily (QD)
Study: 26118427
Drug: Alisporivir (ALV)
Normalized name: ALV-001
DrugBank: Alisporivir (DB12139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisporivir (ALV) 600 mg QD and ribavirin (RBV)
Study: 26118427
Drug: Alisporivir (ALV)
Normalized name: ALV-001
DrugBank: Alisporivir (DB12139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisporivir (ALV) 800 mg QD and ribavirin (RBV)
Study: 7500544
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no EPA treatment), n = 10
Study: 30482392
Drug: Apremilast, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast, 30 mg twice daily
Study: 28057030
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.5 mmol/kg loading dose for 1 hour, followed by 0.15 mmol/kg/h infusion for 23 hours)
Study: 25646324
Drug: High whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High whey protein-, leucine-, and vitamin D-enriched supplement (150 kcal, 21 g protein; 10×/wk)
Study: 25646324
Drug: High whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High whey protein-, leucine-, and vitamin D-enriched supplement
Study: 19302265
Drug: Octreotide at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide at doses >=0.5 mg
Study: 19302265
Drug: Octreotide at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide at doses <0.5 mg
Study: 11920300
Drug: Combination B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination B vaccine
Study: 16931265
Drug: Anterior capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior capsule polishing
Study: 15519082
Drug: Anterior capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior capsule polishing (SI-40 IOL)
Study: 15519082
Drug: Anterior capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior capsule polishing (Silens6 IOL)
Study: 8111941
Drug: Atracurium 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.07 mg.kg‐1
Study: 8111941
Drug: Pancuronium 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.015 mg.kg‐1
Study: 21409424
Drug: Midazolam combined
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam combined with fentanyl (50-100 mg)
Study: 21409424
Drug: Midazolam combined
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam combined with propofol (0.5-2.5 mg/kg)
Study: 21409424
Drug: Midazolam alone
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam alone (1.0-2.0 mg)
Study: 3606929
Drug: Nifedipine infusion
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine infusion
Study: 1682787
Drug: MK-912 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-912 (2 mg)
Study: 6786131
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 6 ml/kg bodyweight
Study: 10690857
Drug: GH +
Normalized name: Delsym Cough + Cold Daytime
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH + LH-releasing hormone analog (LHRH-A)
Study: 8475226
Drug: Arginine chlorhydrate
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine chlorhydrate 0.5 g/kg bw IV over 30 min
Study: 8475226
Drug: Simultaneous DSIP
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous DSIP plus arginine chlorhydrate administration
Study: 8475226
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV infusion
Study: 19995493
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care shared between GPs and community pharmacists
Study: 8579490
Drug: Single transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single transfusion of allogenic bone-marrow suspension
Study: 22190137
Drug: 15 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/day pectin
Study: 22190137
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day pectin
Study: 20211323
Drug: Intracoronary BMC
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary BMC therapy
Study: 17221107
Drug: Fluoxetine (F)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (F) 60 mg/day
Study: 17221107
Drug: Sibutramine (S)
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sibutramine (S) 15 mg/day
Study: 17221107
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) 1,700 mg/day
Study: 1600598
Drug: 400 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/m2 carboplatin plus 800 mg/m2 cyclophosphamide (level 1)
Study: 1600598
Drug: 550 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg/m2 carboplatin plus 1100 mg/m2 cyclophosphamide (level 2)
Study: 1600598
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of carboplatin and cyclophosphamide
Study: 1970266
Drug: ICI 141,292
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 141,292 (Visacor) 50 mg
Study: 1970266
Drug: ICI 141,292
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 141,292 (Visacor) 100 mg
Study: 1970266
Drug: ICI 141,292
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 141,292 (Visacor) 200 mg
Study: 1970266
Drug: ICI 141,292
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 141,292 (Visacor) 300 mg
Study: 30646755
Drug: Device-supported titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Device-supported titration
Study: 30646755
Drug: Routine titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine titration
Study: 12046342
Drug: Lamivudine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (150 mg daily) for 48 weeks
Study: 31746448
Drug: Immediate Release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Release (IR) Nifedipine 20 mg
Study: 31746448
Drug: Sustained Release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained Release (SR) Nifedipine 20 mg
Study: 25203421
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate (0.3 g·kg(‐1) + placebo)
Study: 23361456
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus letrozole
Study: 10588490
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser treatment (20 pps, 150 mJ) only
Study: 10588490
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment first, followed by SRP 6 weeks later
Study: 1679390
Drug: Cadralazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadralazine (10 mg once daily)
Study: 31576162
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen
Study: 28173776
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream
Study: 28324753
Drug: Error augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Error augmentation feedback during training sessions
Study: 187312
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1 (2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU), cyclophosphamide, and methotrexate
Study: 22949107
Drug: Photohardening therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photohardening therapy (311 nm UVB) for 4-9 weeks
Study: 21866654
Drug: Unblocking the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unblocking the interior and purgation method (Chinese drugs infused by enteral nutrition tube)
Study: 15273834
Drug: Methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate treatment for ADHD
Study: 11158461
Drug: Fluconazole (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (6 mg/kg) administered intravenously or by feeding tube every 72 hours until day of life (DOL) 7, then every 24 hours until DOL 28.
Study: 7952033
Drug: Single-dose administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose administration of mephenytoin
Study: 7952033
Drug: Single-dose administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose administration of dextromethorphan
Study: 7952033
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of mephenytoin and dextromethorphan
Study: 7952033
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of mephenytoin and caffeine
Study: 7952033
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of mephenytoin, dextromethorphan, and caffeine
Study: 31192968
Drug: Conventional laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional laser treatment
Study: 31978214
Drug: High-dose induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose induction chemotherapy
Study: 24231592
Drug: Indomethacin submicron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin submicron particle capsules 40 mg 3 times daily
Study: 24231592
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg loading dose, then 200 mg BID)
Study: 20598332
Drug: Propranolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (1 mg/kg per day initially, increased to 4 mg/kg per day within 10 days)
Study: 20598332
Drug: Propranolol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (4 mg/kg per day)
Study: 15889234
Drug: Pioglitazone (15-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15-45 mg/day)
Study: 12243600
Drug: Acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 400 mg orally 3 times daily
Study: 12243600
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg orally twice daily
Study: 12243600
Drug: Valacyclovir 250
Normalized name: valacyclovir 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 250 mg orally twice daily
Study: 29960741
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy in addition to IF electrical stimulation (group A)
Study: 29960741
Drug: Only biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only biofeedback therapy (group B)
Study: 24461582
Drug: Etoricoxib (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (90 mg once daily)
Study: 15067624
Drug: Levosulpiride 25
Normalized name: Levosulpiride 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride 25 mg, 3 times daily
Study: 2669567
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with standardized Bermuda grass pollen extract
Study: 23260547
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose autologous muscle derived cells (1, 2, 4, 8 or 16 × 10(6))
Study: 23260547
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose autologous muscle derived cells (32, 64 or 128 × 10(6))
Study: 17145529
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin plus gemcitabine (PG) (n = 34)
Study: 7571663
Drug: Cefotaxime plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime plus metronidazole (single dose)
Study: 7235354
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg, sublingual)
Study: 7235354
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mg, sublingual)
Study: 28219060
Drug: Low-dose Prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Prednisolone
Study: 28219060
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy only (WAT)
Study: 21613332
Drug: Adjustment group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustment group treatment (6 sessions of 2 hours each)
Study: 21613332
Drug: Adjustment group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustment group treatment
Study: 9058850
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of previous antiarrhythmic drug therapy
Study: 7497561
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg intravenously
Study: 29700127
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 18F‐alfatide II and 18F‐FDG
Study: 26675055
Drug: Intramuscular diphereline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diphereline (twice with a 28‐day interval)
Study: 26675055
Drug: Intramuscular diphereline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diphereline
Study: 22972524
Drug: Desmopressin ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin ODT 25-100 µg
Study: 22972524
Drug: Desmopressin ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin ODT 25-50 µg
Study: 20804428
Drug: Inhalation instruction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation instruction
Study: 17687648
Drug: Epirubicin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 90 mg/sqm and paclitaxel 175 mg/sqm plus gefitinib 250 mg daily from day 1 to 21 (Arm B)
Study: 17687648
Drug: Epirubicin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 90 mg/sqm and paclitaxel 175 mg/sqm plus placebo (Arm C)
Study: 16861734
Drug: L-carnitine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (20 mg/kg, intravenously three times a week after each haemodialysis session)
Study: 9806512
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered during intracavitary brachytherapy
Study: 9806512
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia with 10% lidocaine solution
Study: 2539206
Drug: Naloxone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.3 mg/kg)
Study: 414205
Drug: Prolonged intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged intravenous infusion of trinitrin for 24 hours in 12 cases and during 5 at 7 days in 27 cases
Study: 414205
Drug: Prolonged intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged intravenous infusion of trinitrin
Study: 31010033
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of BPH
Study: 31010033
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of VitD3 and BPH
Study: 27043168
Drug: Gabapentin 100-300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 100-300 mg after each HD session for one month
Study: 15326195
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus a new agent
Study: 15326195
Drug: Carboplatin plus
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin plus a new agent
Study: 9510218
Drug: m-chlorophenylpiperazine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-chlorophenylpiperazine (0.1 mg/kg intravenously)
Study: 2909150
Drug: Aminophylline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (3 mg/kg over 3 minutes)
Study: 2909150
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 ml of saline over 3 minutes)
Study: 1572446
Drug: Flurbiprofen 150
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 150 mg
Study: 6348714
Drug: Flurbiprofen 100
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 100 mg
Study: 26214039
Drug: Dengue vaccine
Normalized name: Dengue vaccine
DrugBank: Dengue tetravalent vaccine, live (DB14764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue vaccine
Study: 31436378
Drug: Lactic acid
Normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactic acid 5% mouth wash 3 times daily
Study: 31436378
Drug: Kenalog in
Normalized name: Kenalog in Orabase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kenalog in Orabase twice daily
Study: 30942009
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional patient controlled epidural analgesia and oral celecoxib)
Study: 25740292
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (40 mg day -1)
Study: 7620686
Drug: Base preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base preparation (vehicle)
Study: 2134659
Drug: He‐Ne‐Laser treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: He‐Ne‐Laser treatment
Study: 30763
Drug: Lorazepam (3.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (3.1 mg daily, b.i.d.)
Study: 11474638
Drug: r-hGH therapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hGH therapy for 6-12 months
Study: 9701130
Drug: 2‐component acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐component acellular pertussis vaccine
Study: 9701130
Drug: 5‐component acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐component acellular pertussis vaccine
Study: 9701130
Drug: Whole‐cell pertussis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole‐cell pertussis vaccine
Study: 7958670
Drug: Sham feeding-induced
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham feeding-induced acid secretion during lox infusion
Study: 3117554
Drug: Buccal nitroglycerin
Normalized name: nitroglycerin Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal nitroglycerin (2.5 mg in 49% and 5.0 mg in 51%)
Study: 22768661
Drug: Alfacalcidol with
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol with 400 mg of elemental calcium daily for 12 months
Study: 22768661
Drug: Menatetrenone with
Normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone with 400 mg of elemental calcium daily for 12 months
Study: 20547822
Drug: Bilateral ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ultrasound-guided TAP blocks (2 x 20 mL 0.5% ropivacaine)